Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
Article excerpt
Highlighted: the sentence this signal was extracted from
MILFORD, Mass. and BURLINGTON, N.C., Oct. 23, 2026 /PRNewswire/ -- Labcorp (NYSE: LH ), a global leader of innovative and comprehensive laboratory services, and Waters Corporation (NYSE: WAT ), a global life sciences and diagnostics leader, today announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp's nationwide laboratory network beginning in late 2026. Cervical cancer is largely preventable through routine screening and early detection of human papillomavirus (HPV), yet millions of women remain overdue for recommended tests. This collaboration is designed to help address persistent cervical cancer screening gaps by bringing more accessible screening options to patients across the United States. Labcorp will provide these HPV testing options to support its clinician programs, Gaps in Care health plan programs, and Labcorp OnDemand consumer channel. 2-8 "Barriers such as privacy, access, and socioeconomic factors can make it difficult to stay current with cervical cancer screening," said Jeff Andrews, M.D., FRCSC, Vice President of Medical Affairs, Waters Advanced Diagnostics, Waters Corporation. 5-7 "We are at the start of a new era in which screening can extend beyond the clinic, enable more personalized risk assessment, and reach people who have historically been underserved. By offering greater flexibility in how and where...
Keep reading with a free account
The rest of this article, and every signal for Waters, is in your free account.
